Rebecca J Ronsley, MD, FRCPC

Rebecca J Ronsley, MD, FRCPC

Specialties

"It is a privilege to care for children and young adults with brain tumors as part of a multidisciplinary team of exemplary, committed care providers here at Seattle Children’s. I continue to be inspired by the strength and resilience of our patients and families."

  • Biography

    Dr. Ronsley is an Attending Physician and pediatric oncologist in the Brain Tumor Program at Seattle Children’s Hospital and Principal Investigator at the Ben Towne Center for Childhood Cancer Research. She is the Program Director for the Pediatric Neuro-Oncology Fellowship and Education Lead for the Brain Tumor Program at Seattle Children’s Hospital. She is a Clinician Scholar and is involved with local and national trials to develop novel therapies for difficult-to-treat pediatric brain tumors. She serves as the Study Chair and Principal Investigator of our local Chimeric Antigen Receptor (CAR) T cell trials: BrainChild-01 (targeting HER2), BrainChild-03 (targeting B7-H3), and BrainChild-04(multi-antigen targeting of HER, EGFR, B7-H3, and IL-13ra2). As well, Dr. Ronsley is interested in survivorship/morbidity reduction for pediatric brain tumor patients and collaborates locally and nationally with the Childhood Cancer Survivorship Study, Craniopharyngioma Working Group, and the International CNS Germ Cell Tumor Consortium.

    Board Certification(s)


    Education

    University of Toronto, Toronto, Ontario, ON

    Residency

    British Columbia Children's Hospital, Vancouver, BC

    Fellowship

    British Columbia Children's Hospital, Vancouver, BC
    Nationwide Children's Hospital, Columbus, OH

    Clinical Interests

    Care of children with central nervous system tumors, early phase clinical trials including CAR-T cell patient care, survivorship and late effects. 

     

    Research Description

    Research interests including using tumor biology to develop novel therapeutic strategies for difficult-to-treat pediatric brain tumors. This includes local and national collaboration on early phase clinical trials for pediatric high-grade glioma and diffuse intrinsic pontine glioma, including the SCH BrainChild CAR-T cell studies. Additional interests include survivorship/morbidity reduction for pediatric brain tumor survivors.

    Research Focus Area

    Early phase trials for CNS Tumors, survivorship and morbidity reduction, medical education

  • Related Resources

    • DIPG Research Program

      DIPG Research Program

      Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas (DMG) are aggressive childhood cancers. The DIPG Research Program at Seattle Children’s focuses on development of new therapies for aggressive brain and central nervous system tumors through optimization of clinical care.

    • Immunotherapy Program

      Offering FDA-approved and investigational treatments using chimeric antigen receptor (CAR) T-cell therapy for more types of relapsed or refractory childhood cancers than any other pediatric healthcare facility.

    • Neuro-Oncology Fellowship

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}

  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}

  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}

  • Clinical Trials and Research Studies

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition(s): {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Rebecca J Ronsley, MD, FRCPC.